Results 281 to 290 of about 219,205 (349)

Reproductive Control in Dogs with Emphasis on Anti-GnRH Immunocastration and Its Behavioral Effects. [PDF]

Vet Sci
Ubilla MJ, Lopez-Bejar M, Siel D, Sáenz L.   +3 more
europepmc   +1 more source

Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia. [PDF]

BMC Urol
Bazarbashi S, Abdelmotal AS, Arabi T, Fallatah W, Alzannan N, Elhassan T, Aseafan M, Mahroos M, Aljishi M, Busbaih A, Aldandan R, Rauf MS, Almugbel FA, Azam F, Almansour M.   +14 more
europepmc   +1 more source

IL-6/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities. [PDF]

Front Immunol
Zhou T, Li Y, Liu Z, Zeng Z, Li T, Chen L, Zhao H, Wu X, Shen Y, Fan H, Zhu X, Zhou Y, Zou L, Zhao D.   +13 more
europepmc   +1 more source

Urinary Cystine/Creatinine Concentrations Before and After Castration in Dogs With Suspected Androgen-Dependent Cystine Urolithiasis. [PDF]

J Vet Intern Med
Larsen JA, Hulsebosch SE, Fine J, Johnson EG, Pires J, Henthorn PS, Westropp JL.   +6 more
europepmc   +1 more source

Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide. [PDF]

J Comp Eff Res
Lowentritt BH, Burbage S, Khilfeh I, Pilon D, Du S, Rossi C, Kinkead F, Diaz L, Brown G.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Lancet, The, 2021
BACKGROUND Lutetium-177 [177Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA), with activity and safety in patients with metastatic castration-resistant prostate ...
Michael S Hofman, Louise Emmett, Amir Iravani   +2 more
exaly   +2 more sources

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Lancet, The, 2010
Stephane Oudard, Mustafa ÖzgÜroglu, Steinbjørn Hansen   +2 more
exaly   +2 more sources

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.

NEJM Evidence, 2022
Abiraterone and Olaparib for Metastatic Prostate CancerPatients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair gene mutation status, received either abiraterone and olaparib or abiraterone and placebo ...
N. Clarke, A. Armstrong, A. Thiery-Vuillemin, M. Oya, N. Shore, E. Loredo, G. Procopio, Juliana de Menezes, G. Girotto, Ç. Arslan, N. Mehra, F. Parnis, E. Brown, F. Schlürmann, J. Joung, M. Sugimoto, J. Virizuela, U. Emmenegger, J. Navrátil, G. Buchschacher, C. Poehlein, E. Harrington, C. Desai, Jinyu Kang, F. Saad   +24 more
semanticscholar   +1 more source